Stocks of Recursion Pharmaceuticals Inc (NASDAQ:RXRX) traded higher last session on Wall Street, up 4.88% to $8.60.
RXRX stock price is now -1.21% away from the 50-day moving average and -3.20% away from the 200-day moving average. The market capitalization of the company currently stands at $2.31B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target of $8, Morgan Stanley recently initiated with Equal-Weight rating for Recursion Pharmaceuticals Inc (NASDAQ: RXRX). On March 16, 2023, Needham recently initiated its ‘Buy’ rating on the stock quoting a target price of $17, while ‘KeyBanc Capital Markets’ rates the stock as ‘Overweight’
In other news, Gibson Christopher, Chief Executive Officer sold 50,000 shares of the company’s stock on Jul 11 ’24. The stock was sold for $373,500 at an average price of $7.47. Upon completion of the transaction, the Chief Executive Officer now directly owns 758,738 shares in the company, valued at $6.53 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jul 10 ’24, Chief Executive Officer Gibson Christopher sold 50,000 shares of the business’s stock. A total of $374,000 was realized by selling the stock at an average price of $7.48. This leaves the insider owning 758,738 shares of the company worth $6.53 million. A total of 25.91% of the company’s stock is owned by insiders.
During the past 12 months, Recursion Pharmaceuticals Inc has had a low of $4.97 and a high of $16.75. As of last week, the company has a debt-to-equity ratio of 0.13, a current ratio of 4.65, and a quick ratio of 4.65. The fifty day moving average price for RXRX is $8.7013 and a two-hundred day moving average price translates $8.8881 for the stock.
The latest earnings results from Recursion Pharmaceuticals Inc (NASDAQ: RXRX) was released for 2024-03-31. The net profit margin was -765.90% and return on equity was -85.19% for RXRX. The company reported revenue of $13.79 million for the quarter, compared to $12.13 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 13.68 percent.
